Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Change in Cash (2023 - 2025)

Historic Change in Cash for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to -$24.4 million.

  • NewAmsterdam Pharma's Change in Cash fell 9467.21% to -$24.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.1 million, marking a year-over-year increase of 13322.45%. This contributed to the annual value of $438.1 million for FY2024, which is 43106.25% up from last year.
  • As of Q3 2025, NewAmsterdam Pharma's Change in Cash stood at -$24.4 million, which was down 9467.21% from -$193.4 million recorded in Q2 2025.
  • NewAmsterdam Pharma's Change in Cash's 5-year high stood at $357.0 million during Q4 2024, with a 5-year trough of -$193.4 million in Q2 2025.
  • In the last 3 years, NewAmsterdam Pharma's Change in Cash had a median value of -$27.1 million in 2025 and averaged $5.5 million.
  • In the last 5 years, NewAmsterdam Pharma's Change in Cash surged by 117915.17% in 2024 and then plummeted by 29043.41% in 2025.
  • Quarter analysis of 3 years shows NewAmsterdam Pharma's Change in Cash stood at -$33.1 million in 2023, then soared by 1179.15% to $357.0 million in 2024, then plummeted by 106.83% to -$24.4 million in 2025.
  • Its last three reported values are -$24.4 million in Q3 2025, -$193.4 million for Q2 2025, and -$27.1 million during Q1 2025.